Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
NCT ID: NCT05308966
Last Updated: 2025-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
204 participants
OBSERVATIONAL
2022-05-03
2025-08-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Meso-Immune study targets these patients included in the early access program with the objective to provide additional results to the CheckMate 743 study and confirm the benefit of using this combination in first-line of treatment in this category of patients.
Total study duration will cover 48 months with an inclusion period of 12 months and a follow-up until 3 years. Patients will be recruited retrospectively starting April 01, 2021 until April 01, 2022.
Meso-Immune study will be proposed to all the GFPC centers that have already included patients in the early access program and other centers wishing to participate, in order to analyze a minimum of 150 patients. The total number of sites is evaluated at around 120.
The principal investigator in each center will identify the patients eligible for the Meso-Immune study and will inform them on the study according to the local regulations.
Patient follow-up will be pursued regularly, in in-patient and out-patient clinics, according to the usual practices of the physicians in each participating center. Reevaluation workups will be pursued according to the practices of each center.
The information related to Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news will be recorded in electronic case-report forms (eCRF).
Qualitative variables will be presented descriptively in the principal analysis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
NCT02716272
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
NCT03225365
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
NCT03504696
Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma
NCT01927419
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
NCT01681212
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient presenting MPS treated with nivolumab and ipilimumab
Adult patients with previously untreated and unresectable Malignant Pleural Mesothelioma (MPM) treated with combination of Nivolumab and Ipilimumab in the setting of the early access program not opposed to the collection of their data
Data collection
Observational study without intervention except retrospective and prospective data collection : Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news ; recorded in electronic case-report forms (eCRF).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data collection
Observational study without intervention except retrospective and prospective data collection : Patient characteristics, MPM characteristics, Treatment characteristics, Disease progression, Rebiopsy, Post treatments, Adverse events, Date and cause of death, Date of last news ; recorded in electronic case-report forms (eCRF).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient enrolled in the French National Health Insurance program or with a third-party payer
* Patient not opposed to the collection of his/her data (an information sheet will be to all living patients; for those who died, documented opposition to data collection in his/her medical file is not required)
Exclusion Criteria
* Patient's explicit refusal to collect his / her data
* Patients not managed at the investigating center and not followed by a center investigator
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Groupe Francais De Pneumo-Cancerologie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christos CHOUAID
Role: STUDY_CHAIR
Groupe Français de Pneumo-Cancérologie (GFPC)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU du Pays d'Aix
Aix-en-Provence, , France
CH Albi
Albi, , France
CHU Angers
Angers, , France
CH Argenteuil
Argenteuil, , France
CH Avignon
Avignon, , France
CH Bastia
Bastia, , France
CH Bayonne
Bayonne, , France
CHU Besançon
Besançon, , France
Clinique Ambroise Paré
Beuvry, , France
CH Bligny
Bligny, , France
Clinique Bordeaux
Bordeaux, , France
Hôpital Ambroise Paré
Boulogne-Billancourt, , France
CHU Morvan
Brest, , France
Clinique Pasteur
Brest, , France
Hôpital Louis Pradel
Bron, , France
CHU Caen
Caen, , France
CH Cannes
Cannes, , France
CH du Cotentin
Cherbourg, , France
CHU Hôpital Montpied
Clermont-Ferrand, , France
Unicancer
Clermont-Ferrand, , France
Hôpital Louis Pasteur
Colmar, , France
CH Dijon Bourgogne
Dijon, , France
CH Eure-Seine
Évreux, , France
Clinique Gentilly
Gentilly, , France
CHD les Oudaries
La Roche-sur-Yon, , France
GH Le Havre
Le Havre, , France
CH du Mans
Le Mans, , France
CH Libourne
Libourne, , France
CHU Lille
Lille, , France
CH de Longjumeau
Longjumeau, , France
Hôpital du Scorff
Lorient, , France
Centre Léon Bérard
Lyon, , France
IPC
Marseille, , France
Hôpital Nord
Marseille, , France
CAC Mougins
Mougins, , France
CH Nevers
Nevers, , France
Clinique Saint Georges
Nice, , France
Centre Antoine Lacassagne
Nice, , France
Institut Curie
Paris, , France
Hôpital Cochin
Paris, , France
Hôpital Bichat
Paris, , France
Hôpital La Pitié-Salpêtrière
Paris, , France
GH Paris Site St Joseph
Paris, , France
Hôpital Haut-Lévèque - Groupe Hospitalier SUD
Pessac, , France
CHU La Mileterie
Poitiers, , France
CH Annecy Genevois
Pringy, , France
CH Cornouaille
Quimper, , France
CHU Ponchailloux
Rennes, , France
Clinique Saint Grégoire
Rennes, , France
Hôpital Charles Nicolle
Rouen, , France
Hôpital privé de la Loire
Saint-Etienne, , France
Insititut de Cancerologie de l'Ouest
Saint-Herblain, , France
HIA Begin
Saint-Mandé, , France
Clinique de l'Estuaire
Saint-Nazaire, , France
CH St Quentin
Saint-Quentin, , France
CH de Saint Malo
St-Malo, , France
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
CHITS Toulon Sainte Musse
Toulon, , France
HIA St Anne
Toulon, , France
Hôpital Larrey
Toulouse, , France
CHRU Bretonneau
Tours, , France
CH Villefranche
Villefranche-sur-Saône, , France
CH Villeurbanne
Villeurbanne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GFPC 04-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.